TriangleNCT01607957 · CITED IN SOURCE DOCUMENTS
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2024-09-19
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Has provided written informed consent 2. Has adenocarcinoma of the colon or rectum 3. Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer 4. ECOG performance status of 0 or 1 5. Is able to take medications orally 6. Has adequate organ function (bone marrow, kidney and liver) 7. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control. Exclusion Criteria: 1. Certain serious illnesses or medical condition(s) 2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration 3. Has received TAS-102 4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies 5. Is a pregnant or lactating female
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Drug: TAS-102
- label
- TAS-102
- type
- EXPERIMENTAL
- intervention Names
- Drug: Placebo
- label
- Placebo
- type
- PLACEBO_COMPARATOR
- interventions
- arm Group Labels
- TAS-102
- description
- 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
- name
- TAS-102
- type
- DRUG
- arm Group Labels
- Placebo
- description
- Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
- name
- Placebo
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- QUADRUPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 800
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy.
- measure
- Overall Survival
- time Frame
- Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
- secondary Outcomes
- description
- Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated.
- measure
- Progression-free Survival
- time Frame
- Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
- description
- An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.
- measure
- Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths
- time Frame
- From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
Full study description
- brief Summary
- The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
- detailed Description
- This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).
Source references
- references
- citation
- Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argiles G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 Jan;31(1):88-95. doi: 10.1016/j.annonc.2019.10.005.
- pmid
- 31912801
- type
- DERIVED
- citation
- Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Gravalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21.
- pmid
- 29274618
- type
- DERIVED
- citation
- Longo-Munoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limon ML, Garcia-Carbonero R. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clin Transl Oncol. 2017 Feb;19(2):227-235. doi: 10.1007/s12094-016-1528-7. Epub 2016 Jul 21.
- pmid
- 27443414
- type
- DERIVED
- citation
- Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.
- pmid
- 25970050
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-0147a97f2d3a8660feec
- requested nct id
- NCT01607957
- primary nct id
- NCT01607957
- source kind
- fda_spl_label
- source record id
- 15b86e86-8940-44e3-921c-2e0b97180ea1
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 2e2bd0927aff5fc5884ba15acd50a1e4b7db991c15cc34cb350c46a002cc04dd
- payload
- application numbers
- NDA207981
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-0147a97f2d3a8660feec
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01607957
- occurrences
- context exact
- Metastatic Colorectal Cancer Previously treated metastatic colorectal cancer (single agent LONSURF) RECOURSE The efficacy of LONSURF was evaluated in RECOURSE (NCT01607957), an international, randomized, double-blind, placebo-controlled study conducted in patients with previously treated metastatic colorectal cancer (mCRC). Key e
- end
- 196
- exact text
- NCT01607957
- start
- 185
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/67/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 15b86e86-8940-44e3-921c-2e0b97180ea1
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- ba8a40f0214a18304a2bdba729ce84cb8d44e950820d4cc5d1a0a38dd197e0a9
- spl effective time
- 20251105
- spl set id
- f5beed22-d71d-4c0d-8dca-2c7317d65d85
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-23b5f6fc9f386d7ffbdd
- requested nct id
- NCT01607957
- primary nct id
- NCT01607957
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
- payload sha256
- ce6c0793ef8da4433deabaff82cbd8fbad9031c42e53c2b1c3695361af8331d1
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-23b5f6fc9f386d7ffbdd
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01607957
- occurrences
- context exact
- "-1">Evidence (trifluridine-tipiracil):</p> <div class="pdq-content-list"><ol id="_1149"><li>A phase III double-blind study (<a href="/clinicaltrials/NCT01607957">RECOURSE</a> [NCT01607957]) randomly assigned 800 patients with stage IV colorectal cancer whose cancer had been refractory to two previous therapies. Patie
- end
- 294085
- exact text
- NCT01607957
- start
- 294074
- context exact
- -tipiracil):</p> <div class="pdq-content-list"><ol id="_1149"><li>A phase III double-blind study (<a href="/clinicaltrials/NCT01607957">RECOURSE</a> [NCT01607957]) randomly assigned 800 patients with stage IV colorectal cancer whose cancer had been refractory to two previous therapies. Patients were required to have r
- end
- 294112
- exact text
- NCT01607957
- start
- 294101
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/000ed4364d31964822.html
- source file sha256
- a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:38.943216+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 387f265965c4b56957c6f58b4d8eb54b8d5a660b7f6ef6c433eff171e69dbb77
- source title
- Rectal Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 12, 2025
- datetime
- 2025-02-12T12:00:00Z
- display
- February 12, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-8541f868a9989df59db8
- requested nct id
- NCT01607957
- primary nct id
- NCT01607957
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- c3362deecde47509664af2cf063d6a1d02687d3d0ea0ee66f5973c4fee17def9
- payload sha256
- 464e9228cddeea045eee7a254e9e9a821f100a9c5bd4969a6acbbec91368af0f
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-8541f868a9989df59db8
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01607957
- occurrences
- context exact
- "-1">Evidence (trifluridine-tipiracil):</p> <div class="pdq-content-list"><ol id="_509"><li>A phase III, double-blind study (<a href="/clinicaltrials/NCT01607957">RECOURSE</a> [NCT01607957]) randomly assigned 800 stage IV colorectal cancer patients whose cancer had been refractory to two previous therapies. Patients
- end
- 236901
- exact text
- NCT01607957
- start
- 236890
- context exact
- -tipiracil):</p> <div class="pdq-content-list"><ol id="_509"><li>A phase III, double-blind study (<a href="/clinicaltrials/NCT01607957">RECOURSE</a> [NCT01607957]) randomly assigned 800 stage IV colorectal cancer patients whose cancer had been refractory to two previous therapies. Patients were required to have recei
- end
- 236928
- exact text
- NCT01607957
- start
- 236917
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/610f1b1dfbdfdb9c66.html
- source file sha256
- c3362deecde47509664af2cf063d6a1d02687d3d0ea0ee66f5973c4fee17def9
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:38.940003+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 58f90914226eeac4b647c55350600c5f4db658e650463c199f43412e56552b42
- source title
- Colon Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 12, 2025
- datetime
- 2025-02-12T12:00:00Z
- display
- February 12, 2025
Preserved source evidence · Independent clinical review pending · Not medical advice